Literature DB >> 25403595

Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified.

Marco Valgimigli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25403595     DOI： 10.1161/CIRCULATIONAHA.114.011319

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

Review 2.  Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina.

Authors:  Taylor C Bazemore; Michael G Nanna; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

3.  Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Authors:  Devraj Sukul; Milan Seth; Simon R Dixon; Akshay Khandelwal; Thomas A LaLonde; Hitinder S Gurm
Journal:  J Invasive Cardiol       Date:  2017-04-15       Impact factor: 2.022

Review 4.  Bleeding avoidance strategies in percutaneous coronary intervention.

Authors:  Davide Capodanno; Deepak L Bhatt; C Michael Gibson; Stefan James; Takeshi Kimura; Roxana Mehran; Sunil V Rao; Philippe Gabriel Steg; Philip Urban; Marco Valgimigli; Stephan Windecker; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2021-08-23       Impact factor: 32.419

Review 5.  Analyzing the Efficacy and Cost-effectiveness of Anti-platelet Therapy in Unstable Angina/Non-ST Elevation Myocardial Infarction: A Decision Analysis.

Authors:  Srikar Reddy; Mevin Mathew; Nimai Patel; Saleh Rahman
Journal:  Cureus       Date:  2019-08-05

6.  Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.

Authors:  Giuseppe Tarantini; Marco Mojoli; Ferdinando Varbella; Roberto Caporale; Stefano Rigattieri; Giuseppe Andò; Plinio Cirillo; Simona Pierini; Andrea Santarelli; Paolo Sganzerla; Nicoletta De Cesare; Ugo Limbruno; Alessandro Lupi; Roberto Ricci; Carlo Cernetti; Luca Favero; Francesco Saia; Loris Roncon; Valeria Gasparetto; Marco Ferlini; Federico Ronco; Luca Ferri; Daniela Trabattoni; Alessandra Russo; Vincenzo Guiducci; Carlo Penzo; Fabio Tarantino; Ciro Mauro; Alfredo Marchese; Battistina Castiglioni; Alessio La Manna; Matteo Martinato; Dario Gregori; Dominick J Angiolillo; Giuseppe Musumeci
Journal:  Trials       Date:  2020-11-24       Impact factor: 2.279

7.  Early Dual-Antiplatelet Therapy at the Emergency Department Is Associated with Lower In-Hospital Major Adverse Cardiac Event Risk among Patients with Non-ST-Elevation Myocardial Infarction.

Authors:  Jen-Han Yang; Hong-Mo Shih; Yan-Cheng Pan; Shih-Sheng Chang; Chi-Yuan Li; Shao-Hua Yu
Journal:  Cardiol Res Pract       Date:  2021-04-22       Impact factor: 1.866

Review 8.  Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome.

Authors:  Korakoth Towashiraporn; Rungroj Krittayaphong
Journal:  Int J Gen Med       Date:  2022-03-03

Review 9.  When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?

Authors:  Pedro Gabriel Melo de Barros e Silva; Henrique Barbosa Ribeiro; Antônio Claudio do Amaral Baruzzi; Expedito Eustáquio Ribeiro da Silva
Journal:  Arq Bras Cardiol       Date:  2016-03       Impact factor: 2.000

10.  P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model.

Authors:  James Gunton; Trent Hartshorne; Jeremy Langrish; Anthony Chuang; Derek Chew
Journal:  J Clin Med       Date:  2016-08-17       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.